Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) issued its quarterly earnings results on Monday. The company reported $3.29 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $1.38, FiscalAI reports. Neurocrine Biosciences had a net margin of 20.91% and a return on equity of 22.43%. The business had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same quarter last year, the business posted $2.04 earnings per share. Neurocrine Biosciences’s revenue for the quarter was up 41.3% compared to the same quarter last year.
Here are the key takeaways from Neurocrine Biosciences’ conference call:
- Record third-quarter performance: Net product sales exceeded $1.1 billion, up more than 40% year over year, while operating profitability and non-GAAP earnings also reached records.
- INGREZZA sales rose 17% to $801 million, prompting the company to raise full-year guidance to $2.9 billion–$2.925 billion. Management expects double-digit volume growth in 2027 to offset mid- to high-single-digit net pricing pressure.
- CRENESSITY sales reached $211 million, supported by steady patient additions, favorable reimbursement, and strong persistence; more than 15% of diagnosed classic CAH patients have now been prescribed the drug. The company is pursuing a study in children under age four that could expand the label.
- VYKAT XR sales reached $107 million, but management acknowledged that recent external safety-related events may delay its growth trajectory. The company expects continued monitoring, education, and a 2027 study in PWS patients with complex comorbidities, while discontinuation trends remain an area it is still evaluating.
- Neurocrine highlighted a catalyst-rich 2027, including Phase III readouts for osavampator in major depressive disorder and direclidine in schizophrenia, plus progress in Alzheimer’s disease, obesity, and Friedreich’s ataxia. The company ended the quarter with approximately $800 million in cash and retains flexibility for disciplined business development.
Neurocrine Biosciences Trading Down 0.5%
NASDAQ:NBIX opened at $145.35 on Tuesday. Neurocrine Biosciences has a 1-year low of $122.14 and a 1-year high of $186.12. The business’s 50-day moving average price is $146.49 and its two-hundred day moving average price is $147.45. The firm has a market capitalization of $14.77 billion, a price-to-earnings ratio of 21.31, a PEG ratio of 0.64 and a beta of 0.36.
Wall Street Analysts Forecast Growth
Several research analysts have issued reports on the company. Weiss Ratings raised Neurocrine Biosciences from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 14th. Wall Street Zen lowered Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Sunday, August 9th. Citigroup lifted their target price on Neurocrine Biosciences from $249.00 to $253.00 and gave the company a “buy” rating in a research note on Thursday, September 3rd. Canaccord Genuity Group boosted their target price on Neurocrine Biosciences from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Finally, TD Cowen boosted their target price on Neurocrine Biosciences from $200.00 to $220.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $201.14.
View Our Latest Report on Neurocrine Biosciences
Insider Transactions at Neurocrine Biosciences
In other news, insider David Boyer sold 826 shares of the business’s stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $157.45, for a total transaction of $130,053.70. Following the completion of the transaction, the insider directly owned 8,722 shares in the company, valued at approximately $1,373,278.90. The trade was a 8.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Matt Abernethy sold 2,311 shares of the company’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $157.20, for a total value of $363,289.20. Following the completion of the sale, the chief financial officer directly owned 42,808 shares of the company’s stock, valued at approximately $6,729,417.60. This trade represents a 5.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 4.60% of the stock is currently owned by company insiders.
Key Neurocrine Biosciences News
Here are the key news stories impacting Neurocrine Biosciences this week:
- Positive Sentiment: Strong third-quarter results: Neurocrine reported adjusted earnings of $3.29 per share, up from $2.04 a year earlier and above consensus estimates ranging from $1.91 to $2.67. Revenue increased 41.3% year over year to approximately $1.12 billion, exceeding the roughly $1.04 billion estimate. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
- Positive Sentiment: Product sales exceeded $1 billion for the first time: Management attributed the milestone to strong demand across its portfolio of medicines, indicating continued commercial momentum and a broader revenue base. Neurocrine Biosciences Crosses $1 Billion in Quarterly Product Sales
- Positive Sentiment: INGREZZA guidance raised: Neurocrine increased its 2026 net sales guidance for INGREZZA (valbenazine) to $2.9 billion-$2.925 billion. The upgraded outlook reinforces expectations for sustained demand for the company’s leading commercial product. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
- Neutral Sentiment: Management’s earnings-call presentations and transcripts provide additional detail on quarterly performance, product demand, and the company’s outlook. Investors will likely focus on whether the strong growth and raised guidance can continue into 2027. Neurocrine Q3 2026 Earnings Call Transcript
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.
Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.
Featured Stories
- Five stocks we like better than Neurocrine Biosciences
- AST SpaceMobile’s Brazil Breakthrough Could Set the Stage for a Q3 Stock Rebound
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
